The effect of orlistat body weight and coronary heart disease risk profile in obese patients: The swedish multimorbidity study

Journal of Internal Medicine

Volumn 248, Issue 3, 2000, Pages 245-254

  Lindgarde, F ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antiobesity agents; Cardiovascular diseases; Drug therapy; Obesity; Type 2 diabetes mellitus; Weight loss

Indexed keywords

ANTIOBESITY AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TETRAHYDROLIPSTATIN;

ADULT; AGED; ARTICLE; BODY WEIGHT; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY RISK; DIET; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCREENING TEST; SWEDEN;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTI-OBESITY AGENTS; CARDIOVASCULAR DISEASES; CHI-SQUARE DISTRIBUTION; DIET, REDUCING; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LACTONES; MALE; MIDDLE AGED; OBESITY; RISK FACTORS; STATISTICS, NONPARAMETRIC; SWEDEN;

EID: 0033823438     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.2000.00720.x     Document Type: Article

References (42)

1. Obesity as an independent risk factor for cardiovascular disease: A 26-year follow-up of participants in the Framingham Heart Study
2. A prospective study of obesity and risk of coronary heart disease in women
3. Body size and fat distribution as predictors of coronary heart disease among middle aged and older US men
4. Body weight, cardiovascular risk and coronary mortality: 15-year follow-up of middle-aged men and women in Eastern Finland
5. Body-mass index and mortality in a prospective cohort of US adults
6. Short-term medical benefits and adverse effects of weight loss
7. Synergistic effects of risk factors
8. Prevalence of cardiovascular disease risk-factor clustering among persons aged ≥ 45 Years - Louisiana 1991-95
9. Clustering of metabolic factors and coronary heart disease
10. Beneficial health effects of modest weight loss
11. A review of long-term studies evaluating the efficacy of weight loss in ameliorating disorders associated with obesity
12. What are the benefits of moderate weight loss?
13. Early and late effects of weight loss on lipoprotein metabolism in severe obesity
14. Long-term effects of modest weight loss in type II diabetic patients
15. Effect of drug and diet treatment of mild hypertension on diastolic blood pressure. The TAIM Research Group
16. Sodium reduction and weight loss in the treatment of hypertension in older persons: A randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group
17. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention
18. Identifying patients at risk for coronary heart disease: Treatment implications
19. Mode of action of orlistat
20. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients
21. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat
22. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study
23. Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmo feasibility study
24. Diet and exercise are equally effective in reducing risk for cardiovascular disease. Results of a randomized controlled study in men with slightly to moderately raised cardiovascular risk factors
25. Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP)
26. Lifestyle modification program in management of patients with coronary artery disease: The clinical experience in a tertiary care hospital
27. No excess 12-year mortality in men with impaired glucose tolerance who participated in the Malmo Preventive Trial with diet and exercise
28. Long-term follow-up of behavioral treatment for obesity: Patterns of weight regain among men and women
29. Evidence for success of calorie restriction in weight loss and control: Summary of data from industry
30. Treatment of obesity by moderate and severe calorie restriction: Results of clinical research trials
31. Three-year follow-up of participants in a commercial weight loss program. Can you keep it off?
32. Efficacy of 24-week monotherapy with acarbose, glibenclamide or placebo in NIDDM patients. The Essen Study
33. Efficacy of 24-week monotherapy with acarbose, metformin or placebo in dietary-treated NIDDM patients. The Essen-II Study
34. Efficacy of metformin in the treatment of NIDDM: Meta-analysis
35. Relative effects of calorie restriction and weight loss in non-insulin-dependent diabetes mellitus
36. Caloric restriction per se is a significant factor in improvements in glycemic control and insulin sensitivity during weight loss in obese NIDDM patients
37. Type II diabetic subjects lose less weight than their overweight spouses
38. United Kingdom Prospective Diabetes Study (UKPDS). 13; Relative efficacy of randomly allocated diet, sulphonylurea, insulin or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years
39. Obesity level and attrition: Support for patient-treatment matching in obesity treatment